Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/127912
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Piñero-Lambea, Carlos | es_ES |
dc.contributor.author | Ruano‑Gallego, David | es_ES |
dc.contributor.author | Fernández, Luis Ángel | es_ES |
dc.date.issued | 2015-12 | - |
dc.identifier.citation | Current Opinion in Biotechnology | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/127912 | - |
dc.description.abstract | Although bacteria are generally regarded as the causative agents of infectious diseases, most bacteria inhabiting the human body are non-pathogenic and some of them can be turned, after proper engineering, into ‘smart’ living therapeutics of defined properties for the treatment of different illnesses. This review focuses on recent developments to engineer bacteria for the treatment of diverse human pathologies, including inflammatory bowel diseases, autoimmune disorders, cancer, metabolic diseases and obesity, as well as to combat bacterial and viral infections. We discuss significant advances provided by synthetic biology to fully reprogram bacteria as human therapeutics, including novel measures for strict biocontainment. | es_ES |
dc.description.sponsorship | Ministerio de Economía y Competitividad (MINECO) (BIO2014- 60305R and BIO2011-26689), BACFITERed (SAF2014-56716-REDT) | es_ES |
dc.description.sponsorship | Comunidad Autónoma de Madrid (S2010-BMD-2312) | es_ES |
dc.description.sponsorship | La Caixa Foundation | es_ES |
dc.description.sponsorship | MINECO (BES-2009-02405) | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation.isversionof | Postprint | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | Bacterial engineering | es_ES |
dc.subject | Bacterial therapies | es_ES |
dc.subject | Cancer | es_ES |
dc.subject | Immune diseases | es_ES |
dc.subject | Synthetic biology | es_ES |
dc.title | Engineered bacteria as therapeutic agents | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1016/j.copbio.2015.05.004 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.1016/j.copbio.2015.05.00 | es_ES |
dc.rights.license | http://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.relation.csic | Sí | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (CNB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
COBIOT-D-15-00008R1.pdf | "Artículo principal" | 696,46 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
78
checked on 20-abr-2024
WEB OF SCIENCETM
Citations
67
checked on 20-feb-2024
Page view(s)
231
checked on 23-abr-2024
Download(s)
1.491
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons